438 related articles for article (PubMed ID: 29759154)
1. MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment.
Landgren O; Lu SX; Hultcrantz M
Semin Hematol; 2018 Jan; 55(1):44-50. PubMed ID: 29759154
[TBL] [Abstract][Full Text] [Related]
2. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.
Landgren O; Devlin S; Boulad M; Mailankody S
Bone Marrow Transplant; 2016 Dec; 51(12):1565-1568. PubMed ID: 27595280
[TBL] [Abstract][Full Text] [Related]
3. MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical Tool.
Landgren O
Semin Hematol; 2018 Jan; 55(1):1-3. PubMed ID: 29759146
[TBL] [Abstract][Full Text] [Related]
4. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.
Landgren O; Iskander K
J Intern Med; 2017 Apr; 281(4):365-382. PubMed ID: 28205262
[TBL] [Abstract][Full Text] [Related]
5. Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.
Landgren O; Owen RG
Cytometry B Clin Cytom; 2016 Jan; 90(1):14-20. PubMed ID: 26147584
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease in multiple myeloma: bringing the bench to the bedside.
Mailankody S; Korde N; Lesokhin AM; Lendvai N; Hassoun H; Stetler-Stevenson M; Landgren O
Nat Rev Clin Oncol; 2015 May; 12(5):286-95. PubMed ID: 25622976
[TBL] [Abstract][Full Text] [Related]
7. New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma.
Landgren O; Rajkumar SV
Clin Cancer Res; 2016 Nov; 22(22):5428-5433. PubMed ID: 28151710
[TBL] [Abstract][Full Text] [Related]
8. Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.
Avet-Loiseau H; Ludwig H; Landgren O; Paiva B; Morris C; Yang H; Zhou K; Ro S; Mateos MV
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):e30-e37. PubMed ID: 31780415
[TBL] [Abstract][Full Text] [Related]
9. Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myeloma.
Braunstein M; Niesvizky R
Semin Oncol; 2016 Dec; 43(6):709-711. PubMed ID: 28061993
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Cavo M; San-Miguel J; Usmani SZ; Weisel K; Dimopoulos MA; Avet-Loiseau H; Paiva B; Bahlis NJ; Plesner T; Hungria V; Moreau P; Mateos MV; Perrot A; Iida S; Facon T; Kumar S; van de Donk NWCJ; Sonneveld P; Spencer A; Krevvata M; Heuck C; Wang J; Ukropec J; Kobos R; Sun S; Qi M; Munshi N
Blood; 2022 Feb; 139(6):835-844. PubMed ID: 34289038
[TBL] [Abstract][Full Text] [Related]
11. What to do with minimal residual disease testing in myeloma.
Manasanch EE
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
[TBL] [Abstract][Full Text] [Related]
12. Multiple Myeloma Minimal Residual Disease.
Paiva B; GarcĂa-Sanz R; San Miguel JF
Cancer Treat Res; 2016; 169():103-122. PubMed ID: 27696260
[TBL] [Abstract][Full Text] [Related]
13. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].
Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022
[No Abstract] [Full Text] [Related]
14. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
15. Requirements for operational cure in multiple myeloma.
Mohty M; Avet-Loiseau H; Harousseau JL
Blood; 2021 Oct; 138(16):1406-1411. PubMed ID: 34324647
[TBL] [Abstract][Full Text] [Related]
16. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
[TBL] [Abstract][Full Text] [Related]
17. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
[TBL] [Abstract][Full Text] [Related]
18. What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series.
Ely S; Biran N; Chari A
Curr Hematol Malig Rep; 2014 Dec; 9(4):379-88. PubMed ID: 25277219
[TBL] [Abstract][Full Text] [Related]
19. [Clinical Significance and Detection Techniques of Minimal Residual Disease in Multiple Myeloma-Review].
Yu Q; Shi JM; Tao Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):961-964. PubMed ID: 28641668
[TBL] [Abstract][Full Text] [Related]
20. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
Martinez-Lopez J; Alonso R; Wong SW; Rios R; Shah N; Ruiz-Heredia Y; Sanchez-Pina JM; Sanchez R; Bahri N; Zamanillo I; Poza M; Buenache N; Encinas C; Juarez L; Miras F; Collado L; Barrio S; Martin T; Cedena MT; Wolf J
J Hematol Oncol; 2021 Aug; 14(1):126. PubMed ID: 34404440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]